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The prognosis of patients infected with HIV type 1 has
improved markedly since the advent of potent antiretroviral
therapies (ARTs). ARTs have enabled sustained suppression of
HIV replication, recovery of the immune system and a
substantial decrease in the frequency of opportunistic
infections. Antiretrovirals may, however, cause life-threatening
complications which include lactic acidosis, pancreatitis,
hypersensitivity reactions, liver toxicity and severe immune
reconstitution inflammatory syndrome.
A subgroup of patients being treated with nucleoside reverse
transcriptase inhibitors (NRTIs) will develop symptomatic
hyperlactataemia and lactic acidosis, a manifestation of
mitochondrial toxicity. 
Using mechanisms similar to those used to inhibit viral
replication, NRTIs also inhibit human mitochondrial DNA
polymerase gamma.1 This inhibition leads to a depletion of
mitochondrial DNA and an alteration in the synthesis of
mitochondrial proteins. Subsequently there is an accumulation
of mutations within mitochondrial DNA; this may lead to
clinical toxicities such as skeletal myopathy, cardiomyopathy,
neuropathy, HIV-associated neuromuscular weakness
syndrome, pancreatitis, hepatic steatosis and lactic acidosis.2
Some NRTIs have a greater affinity for DNA polymerase
gamma and therefore cause lactic acidosis more commonly.
Stavudine (d4T) and didanosine (ddI) have the greatest affinity,
and tenofovir (TDF) and abacavir (ABC) the least (ddI > d4T >
AZT > 3TC = ABC = TDF).  The use of stavudine is the most
frequently identified risk factor.3
Lactic acidosis and symptomatic hyperlactataemia can occur
from 1 month to 20 months after commencing NRTIs.4 Patients
may be asymptomatic, have nonspecific symptoms or be
critically ill. Typical initial symptoms may develop over 1 - 6
weeks5 and include dyspnoea, abdominal complaints
(vomiting, pain and distension), myalgia, fatigue and weight
loss. There may also be associated lipodystrophy and axonal
neuropathy. The development of these conditions will depend
on the patient’s adherence, duration of treatment, the specific
NRTIs used and also the number of NRTIs in the regimen. 
Several factors may predispose a patient to the development
of lactic acidosis/hyperlactataemia.  These include female sex,
excellent compliance, duration of treatment of more than 6
months, chronic muscle or kidney disease, chronic hepatitis B
or C infection, and the combination of d4T and ddI, especially
in pregnancy.5-7 The correlation between women with an
increased body mass index (BMI) and lactic acidosis remains
unproven.  Conditions unrelated to NRTI administration may
also cause lactic acidosis (Table I) and this differential must
always be considered in all patients who present with raised
serum lactate levels.
There is no consensus on criteria or definitions with regard to
raised serum lactate concentrations. Hyperlactataemia is
commonly referred to as one of three clinical and biochemical
entities. 
1. Asymptomatic hyperlactataemia (subclinical
hyperlactataemia). Here the lactate level is mildly or
moderately raised (2.5 - 5 mmol/l, depending on preferred
criteria) and the patient is asymptomatic.8 Up to 25% or more
of patients treated with NRTIs will have an elevated lactate
concentration during their course of treatment, but most (85%)
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Table I. Conditions causing raised serum lactate in the
absence of NRTI use6,7,9
Increased energy levels Exogenous intoxication
Exercise Salicylates
Infection (sepsis) Biguanides
Decreased lactate clearance Isoniazid
Kidney disease Cyanide
Liver disease Methanol
Malignancy Shock/hyperperfusion states
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remain symptom free.9 Hyperlactataemia may be transient or
prolonged and has not been found to predict the onset of
symptomatic or severe lactic acidosis.10 Therefore screening
asymptomatic patients on NRTIs is not considered beneficial.8
The variability in lactate measurements may reflect differences
in venous sampling techniques.9
2. Symptomatic hyperlactataemia. In this category patients
have moderately elevated lactate levels (2.5 - 5 mmol/l), no
acidosis, but are symptomatic.10 The prevalence of this
condition is approximately 8 - 14.5 per 1 000 patient-years.9
This may be an early manifestation before the onset of acute
severe lactic acidosis. Withdrawal of ARTs at this stage usually
leads to good clinical recovery indicating the significance of an
early diagnosis.9
3. Lactic acidosis. The criteria used to diagnose lactic acidosis
include serum lactate > 5 mmol/l, bicarbonate level < 20
mmol/l, arterial pH < 7.34 and anion gap > 12. The incidence
varies from centre to centre but is thought to be in the region of
1 - 5 per 1 000 patient-years.7 These patients are usually
symptomatic and the mortality rate is high. A serum lactate
concentration of > 10 mmol/l is considered an independent
predictor of mortality and a level > 15 mmol/l is associated
with > 60% mortality.4
For an accurate lactate measurement the specimen must be
collected from an uncuffed arm, in a fluoride tube, put on ice
immediately and sent to the laboratory within 4 hours. A
second specimen should be taken to confirm an elevated
lactate.  The patient should be well hydrated and should not
exercise for 24 hours before sampling.11
In resource-poor settings where this is not possible
calculating the anion gap will be helpful as this may alert one
to the presence of a raised serum lactate (anion gap = (Na + K)
– (HCO3 + Cl)).1 A normal anion gap ranges from 6 to 12
mmol/l.
On admission, arterial blood gases, urea and electrolytes and
surrogate markers should be monitored.  Surrogate markers
include lactate dehydrogenase (LDH), creatinine kinase (CK),
amylase, lipase and transaminases.11 The patient should be
assessed for other signs of mitochondrial toxicity including
peripheral neuropathy and lipoatrophy. An abdominal
ultrasound and/or computed tomography (CT) scan should be
performed if pancreatitis is suspected and a liver biopsy should
be considered to confirm a diagnosis of possible hepatic
steatosis.
In those patients with symptomatic hyperlactataemia or lactic
acidosis all antiretroviral medication must be discontinued.9
The need for hospital admission depends on the severity of
symptoms, presence of acidosis and lactate levels. Owing to the
long half-life of mitochondria (4.5 - 8 weeks) the time required
for clinical recovery ranges from 4 to 28 weeks.11
Management is predominantly supportive, namely
intravenous fluid rehydration, dialysis and respiratory support.
There is little evidence to support or negate the administration
of sodium bicarbonate. Administration of essential co-factors
such as thiamine, riboflavin, L-carnitine, vitamin C and
antioxidants have been used anecdotally.4,12 Several published
case reports describing the use of different co-factors at
different dosages suggest they may induce recovery from lactic
acidosis.4 The experience with riboflavin seems the most
extensive.11 However, no adequate controlled trials exist to
support this.
Although the safest treatment option for patients when ready
to be re-challenged with ARTs would be a NRTI-sparing
regimen, i.e. the combination of a protease inhibitor and a non-
nucleoside reverse transcriptase inhibitor, switching to another
NRTI after recovery may be justified.  NRTIs such as TDF,
ABC, 3TC and AZT have a lower affinity for DNA polymerase
gamma and have been used safely.3,11 This may be an option
where fewer antiretroviral drugs are available (public sector) or
in those patients with limited treatment options.  In these
selected cases NRTIs with a lower affinity may be initiated
once lactate measurements have been found to be within the
normal range for 2 - 3 months. Subsequent close monitoring of
lactate levels will be necessary.
In South Africa, as ARTs become more utilised and d4T-
containing regimens remain the first line of treatment, the
prevalence of NRTI-related mitochondrial toxicity can be
expected to increase significantly.  The clinician must be aware
of the risk factors and have a high index of suspicion for these
syndromes in every patient on NRTI therapy. Policy makers
will have to seriously consider the swift registration of newer
and safer antiretroviral drugs available on the international
market and it will become necessary for drug companies to
find innovative ways to make these drugs available to
communities with limited financial resources. 
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